Fixní kombinace dapagliflozin/metformin v léčbě diabetes mellitus 2. typu
| Title in English | Fixed-dose combination dapagliflozin/metformin in the treatment of type 2 diabetes mellitus |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Endocrinology, diabetology, metabolism, nutrition |
| Keywords | SGLT2 inhibitors; gliflozins; dapagliflozin; metformin; Xigduo; type 2 diabetes mellitus |
| Description | The fixed-dose combination dapagliflozin/metformin (Xigduo) represents a new therapeutic option in the clinical practice that can be used as second-choice therapy after metformin monotherapy failure. In contrast to the combination sulfonylurea derivative/metformin that is associated with weight gain, and by contrast with the combination gliptin/metformin that does not have any weight-modifying effects, the new combination, quite to the contrary, reduces bodily weight, and is not burdened with the risk of hypoglycaemia. Another benefit derived from this combination is its antihypertensive effect. It can also be used in combination with insulin therapy. Last but not least, this fixed-dose combination helps to obtain better patient compliance. |